Results 61 to 70 of about 16,704,778 (257)
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
Journal for ImmunoTherapy of Cancer, 2021 Multiple myeloma (MM) remains incurable despite the number of novel therapies that have become available in recent years. Occasionally, a patient with MM will develop an amyloid light-chain (AL) amyloidosis with organ dysfunction.
A. Oliver-Cáldes +27 more
semanticscholar +1 more source
Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
Nature Communications, 2020 Systemic AL amyloidosis is a debilitating and potentially fatal disease that arises from the misfolding and fibrillation of immunoglobulin light chains (LCs).
L. Radamaker +8 more
semanticscholar +1 more source
Cancer Management and Research, 2021 Junhui Xu,* Mangju Wang,* Ye Shen, Miao Yan, Weiwei Xie, Bingjie Wang, Huihui Liu, Xinan Cen Department of Hematology, Peking University First Hospital, Beijing, People’s Republic of China*These authors contributed equally to this ...
Xu J +7 more
doaj
Review Article of Cardiac Amyloidosis
Walailak Journal of Science and Technology, 2011 Cardiac amyloidosis is a term that means the deposit of abnormal proteins in the myocardium leading to global thickening of the heart walls. The clinical character is that of infiltrative cardiomyopathy.
Jittiporn PURATTANAMAL
doaj +1 more source
High-resolution crystal structure of gelsolin domain 2 in complex with the physiological calcium ion [PDF]
Biochem Biophys Res Commun. 2019 Oct 8;518(1):94-99, 2019 The second domain of gelsolin (G2) hosts mutations responsible for a hereditary form of amyloidosis. The active form of gelsolin is Ca2+-bound; it is also a dynamic protein, hence structural biologists often rely on the study of the isolated G2.
arxiv +1 more source
Daratumumab for the treatment of AL amyloidosis [PDF]
Leukemia & Lymphoma, 2018 Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, and immunotherapy with monoclonal ...
M. Hasib Sidiqi, Morie A. Gertz
openaire +3 more sources
Dissection of the amyloid formation pathway in AL amyloidosis
Nature Communications, 2021 In antibody light chain (AL) amyloidosis, overproduced light chain (LC) fragments accumulate as fibrils in organs and tissues of patients. In vitro, AL fibril formation is a slow process, characterized by a pronounced lag phase.
P. Kazman +3 more
semanticscholar +1 more source
A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots
Frontiers in MedicineBackgroundLight chain (AL) amyloidosis stands as the most prevalent subtype of systemic amyloidosis, encompassing a group of rare diseases. Here, we evaluated the scientific landscape of AL amyloidosis to investigate research trends and identify hotspots
Xiangdong Liu +19 more
doaj +1 more source
Biomarker Research, 2023 Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell +8 more
doaj +1 more source
Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021
Diagnostics, 2021 Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li +6 more
doaj +1 more source